<DOC>
	<DOCNO>NCT02171520</DOCNO>
	<brief_summary>The objective demonstrate bioequivalence capsule make 2 different drug product batch . The reference batch representative current commercial drug product pivotal Phase III batch . The test batch drug product batch intend future commercial use .</brief_summary>
	<brief_title>Bioequivalence Two Different Generations Drug Product Dabigatran Etexilate Following Oral Administration Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead electrocardiogram , clinical laboratory test 2 . Age ≥60 ≤85 year 3 . Body mass index ( BMI ) ≥18.5 BMI ≤30.0 kg/m2 4 . Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : 1 . Clinically relevant gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Clinically relevant surgery gastrointestinal tract 3 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 4 . Any relevant bleeding history 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator 8 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 9 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial 10 . Participation another trial investigational drug within four week prior administration trial 11 . Alcohol abuse ( 60 g/day men 40 g/day woman ) 12 . Drug abuse 13 . Blood donation ( 100 mL within four week prior administration trial ) 14 . Excessive physical activity ( within one week prior administration trial ) 15 . Any laboratory value outside reference range clinical relevance ( especially hemoglobin activate partial thromboplastin time ) positive drug virus screen 16 . Planned surgery within four week follow endof study examination 17 . Inability understand protocol requirement , instruction studyrelated restriction , nature , scope , possible consequence study 18 . Unlikely comply protocol requirement , instruction studyrelated restriction ; e.g. , uncooperative attitude , inability return followup visit , improbability complete study 19 . Subject Investigator SubInvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct study 20 . Intake medication , influence blood clotting , i.e. , acetylsalicylic acid , coumarin etc . within 10 day prior administration 21 . Vulnerable subject ( e.g . person keep detention ) 22 . Male subject agree minimise risk female partner become pregnant first dose day completion post study medical examination . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive since least two month )</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>